Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05721755 | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 3 | 290 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 |
| clinicaltrials |
| NCT05752149 | Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial(STELLAR) | recruiting | Phase 2 | 27 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05799274 | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors(RAD301) | active not recruiting | Phase 1 | 9 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07513389 | Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) | recruiting | Phase 2 | 36 | Medical University of South CarolinaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07808359 | Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma(APOLO) | not yet recruiting | Phase 2 | 58 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140500 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 170 | Hoffmann-La RocheINDUSTRY | 9 | Sep 11, 2026 | clinicaltrials |
| NCT04444921 | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | active not recruiting | Phase 3 | 205 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06055868 | People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity | active not recruiting | — | 133 | University of California, San FranciscoOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06487403 | HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers(HN-Bio 02) | recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06557889 | Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas(REDUCE) | active not recruiting | Phase 2 | 86 | Institut Claudius RegaudOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT07714538 | Breath Research Narrow Validation for Gastrointestinal Cancer Detection(BRAVE) | recruiting | — | 1,000 | Imperial College LondonOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815197 | Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer(PERSEUS) | not yet recruiting | Phase 2 | 37 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01142388 | Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | active not recruiting | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | active not recruiting | Phase 1 | 152 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03233711 | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | active not recruiting | Phase 3 | 344 | National Cancer Institute (NCI)NIH | 2 | Sep 10, 2026 | clinicaltrials |
| NCT04868162 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | completed | Phase 2 | 70 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07026474 | Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC(RePaIr-HN) | recruiting | Phase 3 | 214 | Universität des SaarlandesOTHER | 2 | Sep 10, 2026 | clinicaltrials |
| NCT07462377 | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | recruiting | Phase 1 | 110 | EpiBiologicsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07513324 | Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) | not yet recruiting | Phase 2 | 116 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07698886 | Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel | recruiting | Phase 2 | 70 | KTH BiopharmaINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811752 | Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812467 | Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | recruiting | Phase 1 | 100 | SK Life Science, Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | not yet recruiting | Phase 1 | 74 | TwoStep Therapeutics, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT04080804 | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | active not recruiting | Phase 2 | 80 | Dan ZandbergOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04590963 | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer(INTERLINK-1) | active not recruiting | Phase 3 | 370 | AstraZenecaINDUSTRY | 23 | Sep 9, 2026 | clinicaltrials |
| NCT04947241 | Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC | active not recruiting | Phase 1 | 20 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05343325 | The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC | active not recruiting | Phase 2 | 25 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06597721 | ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 210 | Adcendo ApSINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07668154 | A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants | recruiting | Phase 2 | 120 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809100 | Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma(MIC-VADS) | not yet recruiting | N/A | 120 | Centre Hospitalier Sud FrancilienOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809178 | China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm(ChTTSRUIA) | not yet recruiting | — | 608 | Cheng senOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809191 | Hair Regrowth Following Partial Thickness Removal of SSCIS | not yet recruiting | N/A | 15 | The Cooper Health SystemOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT04997902 | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | completed | Phase 1 / Phase 2 | 45 | Kura Oncology, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07090070 | Evaluating Treatment Strategies for p53 Mutant Oral Cancer and Oral Cancer Precursors(p53 RCT) | recruiting | N/A | 636 | University of British ColumbiaOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806500 | Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 | 18 | Beijing Anjianxi Bio-Medical Technology Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807163 | A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC(FORTIFI-FLEX) | recruiting | Phase 2 | 160 | Bicara TherapeuticsINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT04391049 | Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery | active not recruiting | Phase 1 | 16 | NRG OncologyOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05751512 | A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN | recruiting | Phase 3 | 180 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05816785 | Pilot Study of Imatinib Cetuximab Combo for H & N Cancer | completed | Early Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors(NEXUS-01) | recruiting | Phase 1 | 420 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | recruiting | Phase 1 | 540 | PfizerINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT07281417 | Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma | recruiting | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07804966 | Sac-TMT in Vaginal and Vulvar Cancers(ARCANA) | not yet recruiting | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials